Results 271 to 280 of about 117,553 (304)

Recurrent drug-induced liver injury in pediatric living donor liver transplantation: a case report. [PDF]

World J Emerg Med
Zhu X, Zhou X, Yu L, Dai H.
europepmc   +1 more source

Efficacy of bleomycin and sirolimus in inhibiting CD31⁺ endothelial cell proliferation in noninvoluting congenital hemangiomas. [PDF]

Front Cell Dev Biol
Li Y, Wang C, Li Y, Zhu X, Bao J, Ji Y.
europepmc   +1 more source

Curious Coexistence of Perivascula Epitheloid Cell Tumour (PEComa) Systemic Sclerosis-Associated Interstitial Lung Disease and Biopsy-Proven Lymphangioleiomyomatosis in a Middle-Aged Female: A Case Report. [PDF]

Cureus
Isse S, Shafiq I, Dimashkieh H, Quadri A, Khan S.   +4 more
europepmc   +1 more source

Case Report: Life-threatening Kasabach-Merritt phenomenon in a 2-month-old child. [PDF]

Front Pediatr
Wong Grossman AV, Forero JP, Yu JS, Gilbert MM, Anand KJS.   +4 more
europepmc   +1 more source

Personalized sirolimus regimen for vascular malformations: a retrospective analysis of VASE cohort

Seront E, Damme AV, Coulie J, Vikkula M, Boon LM.   +4 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Long‐term outcomes of sirolimus treatment for kaposiform hemangioendothelioma: Continuing successes and ongoing challenges

International Journal of Cancer, 2023
Treatment with sirolimus, an inhibitor of the mammalian target of rapamycin pathway, has improved the prognosis of patients with kaposiform hemangioendothelioma (KHE). However, the efficacy, durability and tolerability of long‐term sirolimus treatment in
Jiangyuan Zhou, Yanan Li, T. Qiu, Xue Gong, Kaiying Yang, Xuepeng Zhang, Zixin Zhang, Yuru Lan, F. Hu, Qiang Peng, Yongbo Zhang, Feiteng Kong, Siyuan Chen, Yi Ji   +13 more
semanticscholar   +1 more source

Molecular actions of sirolimus: sirolimus and mTor

Transplantation Proceedings, 2003
Recent therapeutic strategies to combat organ allograft rejection have focused on T-cell signaling pathways and the molecules that comprise them. The macrolide antibiotic produced by the bacterium Streptomyces hygroscopicus, known as sirolimus or rapamycin, has shown great therapeutic potential in the transplant setting.
R A, Kirken, Y L, Wang
openaire   +2 more sources

Propranolol‐resistant infantile hemangioma successfully treated with sirolimus

Pediatric dermatology, 2020
Infantile hemangiomas are the most common benign vascular tumors in childhood. Propranolol is the first‐line treatment for infantile hemangiomas, but failures may occur.
Victoria L Dávila-Osorio, H. Iznardo, E. Roé, L. Puig, E. Baselga   +4 more
semanticscholar   +1 more source

Long‐term follow‐up after sirolimus‐coated balloon use for coronary artery disease. Final results of the Nanolutè study

Catheterization and cardiovascular interventions, 2020
To test the long‐term efficacy of a sirolimus‐coated balloon (SCB).
Rami El-Mokdad, G. di Palma, B. Cortese
semanticscholar   +1 more source

Treatment of superficial vascular anomalies with topical sirolimus: A multicenter case series

Pediatric dermatology, 2020
Systemic sirolimus (rapamycin) has recently been found effective in treating complex vascular anomalies by reducing the size and associated complications.
M. Dodds, M. Tollefson, L. Castelo-Soccio, M. Garzon, M. Hogeling, K. Hook, Christina Boull, Sheilagh M Maguiness   +7 more
semanticscholar   +1 more source